Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More EU Clinical Data Requirements Coming With New Regulations

Executive Summary

In the EU, a two-step strengthening of requirements for clinical data means manufacturers and notified bodies need to act now, well ahead of the new Medical Device Regulations taking effect. Sarah Sorrel, president of device clinical research organization Medpass International, explains how and why in this guest column.

You may also be interested in...



Brexit + MDR Equals Little Certainty For UK And EU Medtech Groups

Medtech stakeholders were reminded recently at the UK's largest regulatory forum that even those willing to make the best of Brexit are still working in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.

New EU Scrutiny Procedure Less Widely Applicable And Less Complex Than Expected

One of the greatest hurdles in the future medtech Regulations – the highly demanding scrutiny procedures for high-risk devices and IVDs – now looks less widely applicable than industry had expected. Amanda Maxwell spoke with MedTech Europe’s John Brennan and Jesus Rueda to find out more

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel